Osiris Therapeutics

Osiris Therapeutics is a company that researches, develops, manufactures, markets, and distributes regenerative medicine products. Its product Grafix is a cryopreserved placental membrane for treating acute and chronic wounds, venous leg ulcers, and burns. In addition, the company offers BIO4, a bone allograft for use in all surgical applications, including spine, trauma, extremity, cranial, and foot and ankle surgery, and Cartiform, a viable chondral allograft that promotes articular cartilage repair to treat focal chondral defects.

Employee Rating

2.4More
TypeSubsidiary
Parent CompanySmith & Nephew
HQColumbia, US
Founded1992
Websiteosiris.com
Cybersecurity ratingCMore
Osiris Therapeutics was founded in 1992 and is headquartered in Columbia, US

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Osiris Therapeutics

Samson Tom

Samson Tom

President and CEO
Jason Keefer

Jason Keefer

Chief Commercial Officer
Alla Danilkovitch

Alla Danilkovitch

Chief Scientific Officer
Show more

Osiris Therapeutics Office Locations

Osiris Therapeutics has an office in Columbia
Columbia, US (HQ)
7015 Albert Einstein Dr
Show all (1)

Osiris Therapeutics Financials and Metrics

Summary Metrics

Founding Date

1992

Total Funding

$65 m

Investors

In total, Osiris Therapeutics had raised $65 m. Osiris Therapeutics is a subsidiary of Smith & Nephew

Osiris Therapeutics Revenue

Embed Graph
View revenue for all periods
Osiris Therapeutics's revenue was reported to be $142.82 m in FY, 2018
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2017FY, 2018

Revenue

41.1m7.8m24.3m59.9m118.5m142.8m

Cost of goods sold

531.0k2.6m6.7m13.2m32.7m38.1m

Gross profit

40.6m5.3m17.7m46.7m85.8m104.7m

Gross profit Margin, %

99%67%73%78%72%73%
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2018Q2, 2018Q3, 2018

Revenue

10.2m10.2m3.4m1.6m2.2m4.1m5.3m6.9m10.1m13.3m17.2m21.0m23.7m25.3m31.6m33.9m36.5m

Cost of goods sold

55.0k139.0k387.0k552.0k732.0k1.1m1.5m1.9m2.2m2.9m3.8m4.6m5.1m5.4m8.9m9.7m9.8m

Gross profit

10.2m10.1m3.1m1.1m1.4m2.9m3.8m5.0m7.8m10.4m13.4m16.4m18.5m19.9m22.8m24.2m26.7m

Gross profit Margin, %

99%99%89%66%66%72%72%73%78%78%78%78%78%79%72%71%73%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2017FY, 2018

Cash

1.7m1.9m2.4m2.2m3.1m16.4m

Accounts Receivable

728.0k3.1m7.5m24.3m26.1m22.5m

Prepaid Expenses

470.0k603.0k355.0k650.0k2.9m3.5m

Inventories

767.0k1.3m1.9m10.9m11.3m9.6m
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2017FY, 2018

Net Income

14.9m(11.1m)8.8m36.9m

Depreciation and Amortization

745.0k708.0k587.0k940.0k688.0k873.0k

Inventories

(511.0k)(651.0k)(9.0m)88.0k135.0k

Accounts Payable

(912.0k)246.0k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2018Q2, 2018Q3, 2018

Net Income

5.8m9.8m(1.3m)(5.5m)(8.5m)(2.7m)(6.5m)1.4m2.5m622.0k(2.3m)164.0k4.4m

Depreciation and Amortization

375.0k560.0k177.0k348.0k528.0k185.0k369.0k273.0k214.0k441.0k685.0k267.0k547.0k850.0k211.0k426.0k658.0k

Inventories

(333.0k)(418.0k)(394.0k)(408.0k)(3.6m)(6.9m)(1.0m)(2.4m)(4.7m)262.0k(616.0k)(536.0k)

Accounts Payable

(1.2m)21.0k101.0k449.0k267.0k(33.0k)
USDQ2, 2011

Financial Leverage

1.8 x
Show all financial metrics

Osiris Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

77/100

SecurityScorecard logo

Osiris Therapeutics Online and Social Media Presence

Embed Graph

Osiris Therapeutics News and Updates

Global Stem Cell Characterization and Analysis Tool Market Future Forecast 2020-2025| Osiris Therapeutics, Inc., Cytori Therapeutics, Inc., Astellas Pharma Inc.

This report also researches and evaluates the impact of Covid-19 outbreak on the Stem Cell Characterization and Analysis Tool industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Stem Cell Characterization and Analysis T…

Osiris Therapeutics, Inc. Announces Closing of Acquisition by Smith & Nephew plc

COLUMBIA, Md., April 17, 2019 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today that it has completed the previously announced sale of Osiris t…

OSIRIS SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces an Investigation of Osiris Therapeutics, Inc. (OSIR) Over the Proposed Merger of the Company with Smith & Nephew plc

NEW YORK, March 27, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating the proposed merger of Osiris Therapeutics, Inc. ("OSIRIS" or the "Company") (NASDAQ:OSIR) with Smith & Nephew plc. Click here for more information:...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Osiris Therapeutics, Inc.

NEW YORK, March 15, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Osiris Therapeutics, Inc. ("OSIR" or the "Company") (NASDAQ: OSIR) in connection with the proposed acquisition of the Company ...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Osiris Therapeutics, Inc. - OSIR

NEW YORK, March 13, 2019 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Osiris Therapeutics, Inc. ("Osiris" or the "Company") (NasdaqGM:...

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Osiris Therapeutics, Inc.

NEW YORK, March 12, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Osiris Therapeutics, Inc. (NASDAQ: OSIR) and its board of directors for breach of fiduciary duty concerning the proposed acquisition of the company by Smith & Nephew plc. Stockholders will...
Show more

Osiris Therapeutics Blogs

Osiris Announces Implementation of Prestige LyotechnologySM Preservation Method Allowing Ambient Storage of Living Tissues

The post Osiris Announces Implementation of Prestige LyotechnologySM Preservation Method Allowing Ambient Storage of Living Tissues appeared first on Osiris Therapeutics, Inc..
Show more

Osiris Therapeutics Frequently Asked Questions

  • When was Osiris Therapeutics founded?

    Osiris Therapeutics was founded in 1992.

  • Who are Osiris Therapeutics key executives?

    Osiris Therapeutics's key executives are Samson Tom, Jason Keefer and Alla Danilkovitch.

  • How many employees does Osiris Therapeutics have?

    Osiris Therapeutics has 267 employees.

  • What is Osiris Therapeutics revenue?

    Latest Osiris Therapeutics annual revenue is $142.8 m.

  • What is Osiris Therapeutics revenue per employee?

    Latest Osiris Therapeutics revenue per employee is $534.9 k.

  • Who are Osiris Therapeutics competitors?

    Competitors of Osiris Therapeutics include AlphaCord, BioServe Biotechnologies and GATC Biotech.

  • Where is Osiris Therapeutics headquarters?

    Osiris Therapeutics headquarters is located at 7015 Albert Einstein Dr, Columbia.

  • Where are Osiris Therapeutics offices?

    Osiris Therapeutics has an office in Columbia.

  • How many offices does Osiris Therapeutics have?

    Osiris Therapeutics has 1 office.